Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTS NASDAQ:KURA NASDAQ:ORKA NASDAQ:SAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTSALT5 Sigma$8.97+9.7%$8.16$1.38▼$10.95$180.68M2.17258,110 shs570,076 shsKURAKura Oncology$5.54-7.0%$6.21$5.41▼$21.57$480.86M0.411.36 million shs3.43 million shsORKAOruka Therapeutics$13.09-4.2%$13.10$5.49▼$52.32$490.10M-0.35138,709 shs71,538 shsSAGESage Therapeutics$8.68$8.55$4.62▼$11.44$543.54M0.263.63 million shsN/AThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTSALT5 Sigma0.00%+42.83%+18.49%+48.26%+584.73%KURAKura Oncology0.00%-7.97%-12.89%-3.99%-70.17%ORKAOruka Therapeutics0.00%-3.75%-6.97%+37.21%+1,308,999,900.00%SAGESage Therapeutics0.00%0.00%-5.75%+32.32%+4.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTSALT5 Sigma0.0075 of 5 stars0.01.00.00.00.00.00.0KURAKura Oncology3.4363 of 5 stars3.41.00.04.71.00.80.6ORKAOruka Therapeutics3.1364 of 5 stars3.60.00.00.03.92.50.6SAGESage Therapeutics3.7345 of 5 stars2.05.00.04.12.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTSALT5 Sigma 0.00N/AN/AN/AKURAKura Oncology 2.86Moderate Buy$24.50342.24% UpsideORKAOruka Therapeutics 3.20Buy$40.38208.44% UpsideSAGESage Therapeutics 1.93Reduce$7.85-9.56% DownsideCurrent Analyst Ratings BreakdownLatest ALTS, KURA, SAGE, and ORKA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.007/21/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.007/8/2025SAGESage TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.206/26/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/20/2025SAGESage TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.006/17/2025SAGESage TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.506/17/2025SAGESage TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHold ➝ Hold$8.00 ➝ $9.006/17/2025SAGESage TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$12.006/17/2025SAGESage TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$8.00 ➝ $8.506/16/2025SAGESage TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTSALT5 Sigma$12.53M14.42N/AN/A$0.49 per share18.31KURAKura Oncology$53.88M8.92N/AN/A$5.32 per share1.04ORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ASAGESage Therapeutics$41.24M13.18N/AN/A$5.89 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTSALT5 Sigma-$6.24MN/A0.00∞N/A-38.58%-113.79%-8.96%N/AKURAKura Oncology-$173.98M-$2.26N/AN/AN/AN/A-52.32%-29.59%N/AORKAOruka Therapeutics-$83.72M-$4.51N/AN/AN/AN/A-25.66%-23.39%N/ASAGESage Therapeutics-$400.67M-$4.89N/AN/AN/A-427.78%-67.10%-58.42%N/ALatest ALTS, KURA, SAGE, and ORKA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025KURAKura Oncology$0.15-$0.75-$0.90-$0.75$64.95 million$15.29 million7/30/2025Q2 2025SAGESage Therapeutics-$0.96-$0.79+$0.17-$0.79$16.69 million$31.66 million5/14/2025Q1 2025ORKAOruka Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTSALT5 SigmaN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ASAGESage TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTSALT5 Sigma1.260.830.83KURAKura Oncology0.026.166.16ORKAOruka TherapeuticsN/A30.0330.03SAGESage TherapeuticsN/A9.169.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTSALT5 Sigma6.27%KURAKura OncologyN/AORKAOruka Therapeutics56.44%SAGESage Therapeutics99.22%Insider OwnershipCompanyInsider OwnershipALTSALT5 Sigma4.90%KURAKura Oncology6.40%ORKAOruka Therapeutics24.69%SAGESage Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTSALT5 Sigma17020.14 million19.16 millionN/AKURAKura Oncology13086.80 million81.24 millionOptionableORKAOruka TherapeuticsN/A37.44 million28.20 millionN/ASAGESage Therapeutics69062.62 million59.18 millionOptionableALTS, KURA, SAGE, and ORKA HeadlinesRecent News About These CompaniesWhy Are Supernus Pharmaceuticals (SUPN) Shares Soaring TodayAugust 6, 2025 | finance.yahoo.comGSA Capital Partners LLP Increases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)August 5, 2025 | marketbeat.comFederated Hermes Inc. Increases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)August 3, 2025 | marketbeat.comAnalysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Price Target at $8.02August 3, 2025 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Upgraded to "Hold" at Wall Street ZenAugust 2, 2025 | americanbankingnews.comWall Street Zen Upgrades Sage Therapeutics (NASDAQ:SAGE) to HoldAugust 2, 2025 | marketbeat.comSage (SAGE) Q2 Revenue Jumps 264%August 1, 2025 | aol.comASupernus strengthens neuropsychiatric portfolio with Sage TherapeuticsAugust 1, 2025 | finance.yahoo.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from BrokeragesJuly 31, 2025 | marketbeat.comSage Therapeutics Announces Second Quarter 2025 Financial ResultsJuly 31, 2025 | finance.yahoo.comSage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue EstimatesJuly 30, 2025 | zacks.comSage Therapeutics (NASDAQ:SAGE) Sees Strong Trading Volume - Time to Buy?July 30, 2025 | marketbeat.comMonaco Asset Management SAM Takes $3.51 Million Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)July 30, 2025 | marketbeat.comCerity Partners LLC Purchases New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)July 27, 2025 | marketbeat.comBML Capital Management LLC Buys New Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE)July 26, 2025 | marketbeat.comEurope's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug YeytuoJuly 25, 2025 | fiercepharma.comFCwm LLC Acquires 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)July 25, 2025 | marketbeat.comSage Therapeutics (SAGE) Expected to Announce Earnings on WednesdayJuly 23, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Sees Large Volume Increase - What's Next?July 22, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Shares Pass Above Fifty Day Moving Average - Should You Sell?July 16, 2025 | marketbeat.comSAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGEJuly 14, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 2025View Why the American Eagle Stock Rally Isn't Just Speculation 3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonThis Drone Stock Is on Sale Despite Big Army ContractBy Jeffrey Neal Johnson | July 31, 2025View This Drone Stock Is on Sale Despite Big Army Contract3 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025View 3 Stocks Riding the AI Data Center Buildout WaveBuybacks Over Dividends? These 2 Stock Picks Make a Strong CaseBy Gabriel Osorio-Mazilli | August 7, 2025View Buybacks Over Dividends? These 2 Stock Picks Make a Strong CaseALTS, KURA, SAGE, and ORKA Company DescriptionsALT5 Sigma NASDAQ:ALTS$8.97 +0.79 (+9.66%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$9.64 +0.67 (+7.46%) As of 08/8/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.Kura Oncology NASDAQ:KURA$5.54 -0.42 (-7.05%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$5.54 0.00 (0.00%) As of 08/8/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Oruka Therapeutics NASDAQ:ORKA$13.09 -0.58 (-4.24%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$13.10 +0.02 (+0.11%) As of 08/8/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Sage Therapeutics NASDAQ:SAGE$8.68 0.00 (0.00%) As of 07/31/2025Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
